DNlite-IVD103

Model: DNlite-IVD103

Exhibitor: BIO PREVENTIVE MEDICINE CORP.

Booth No: N406

Characteristic

DNlite, a prognostic test for diabetic kidney disease (DKD), has received regulatory approval from the Taiwan FDA (TFDA) as well as market access in over 40 countries, including compliance with the EU IVDR. It has also been included in the latest edition of the "2024 Taiwan Clinical Practice Guidelines for Diabetic Kidney Disease" published by the Diabetes Association of the Republic of China (Taiwan) , and has received endorsements from international experts in DKD.

The key features of DNlite lie in its ability to enhance prognostic evaluation of kidney function and risk assessment of renal disease. The goal is to enable early detection and timely intervention, thereby reducing the incidence of end-stage renal disease (ESRD) in Taiwan and promoting better kidney health for the population.